VolitionRx transferred its Nu.Q NETs assay onto Sysmex’s platform, setting up talks on a broader commercial agreement.
The move positions the sepsis-focused test for potential deployment on Sysmex analyzers, strengthening licensing prospects with major diagnostics groups.
The update also cited active licensing discussions with more than a dozen global diagnostic and liquid biopsy companies.
VNRX•
